Table 1 Demographic and clinical characteristics of the study patients
UC (n = 35) | CD (n = 252) | |
|---|---|---|
Observational period, months, median (min, max) | 27.6 (24, 60) | 40.0 (24, 60) |
Male, n (%) | 19 (54.3) | 188 (74.6) |
Age, years, mean (SD) | 43.1 (14.2) | 31.9 (11.3) |
BMI, mean (SD) | 19.48 (2.47) | 18.90 (2.98) |
Extraintestinal manifestations within 2 years, n (%) | 4 (11.4) | 4 (1.6) |
Duration of IBD, years, median (IQR) | ||
Since appearance of IBD symptoms | 3.0 (1.0, 6.0) | 3.0 (1.0, 6.0) |
Since diagnosis | 1.0 (0.0, 4.0) | 0.0 (0.0, 1.0) |
IBD-related surgery since diagnosis, n (%)a | 0 (0) | 65 (26.6) |
UC disease location at diagnosis, n (%) | ||
Proctitis involvement limited to the rectum | 2 (5.7) | – |
Left-sided involvement limited to the proportion of the colon distal to the splenic flexure | 7 (20.0) | – |
Extensive involvement extends proximal to the splenic flexure, including pancolitis | 21 (60.0) | – |
Unknown | 5 (14.3) | – |
CD disease location at diagnosis, n (%)b | ||
Ileal with upper GI disease (L1 + L4) | – | 21 (8.3) |
Ileal without upper GI disease (L1) | – | 18 (7.1) |
Colonic with upper GI disease (L2 + L4) | – | 19 (7.5) |
Colonic without upper GI disease (L2) | – | 30 (11.9) |
Ileocolonic with upper GI disease (L3 + L4) | – | 32 (12.7) |
Ileocolonic without upper GI disease (L3) | – | 104 (41.3) |
Unknown | – | 28 (11.1) |
Disease activity, n (%) | ||
Normal | 0 (0.0) | 13 (5.2) |
Mild | 0 (0.0) | 25 (9.9) |
Moderate | 4 (11.4) | 34 (13.5) |
Severe | 22 (62.9) | 24 (9.5) |
Unknown | 9 (25.7) | 156 (61.9) |
Biochemical activity, n (%) | ||
Normal | 5 (14.3) | 52 (20.6) |
Active | 26 (74.3) | 159 (63.1) |
Unknown | 4 (11.4) | 41 (16.3) |
Disease behavior, n (%)b | ||
Non-stricturing, non-penetrating with perianal disease (B1p) | – | 60 (23.8) |
Non-stricturing, non-penetrating without perianal disease (B1) | – | 49 (19.4) |
Stricturing with perianal disease (B2p) | – | 40 (15.9) |
Stricturing without perianal disease (B2) | – | 30 (11.9) |
Penetrating with perianal disease (B3p) | – | 17 (6.7) |
Penetrating without perianal disease (B3) | – | 23 (9.1) |
Unknown | – | 33 (13.1) |
Prior non-biologic therapy, n (%) | ||
Yes | 27 (77.1) | 101 (40.1) |
No | 7 (20.0) | 147 (58.3) |
Unknown | 1 (2.9) | 4 (1.6) |
Prior non-biologic therapy, n (%) | ||
Aminosalicylates | 21 (77.8) | 66 (65.3) |
Antibiotics | 9 (33.3) | 20 (19.8) |
Corticosteroids | 16 (59.3) | 47 (46.5) |
Immunosuppressants | 11 (40.7) | 47 (46.5) |
Azathioprine | 6 (22.2) | 44 (43.6) |
Mercaptopurine | 3 (11.1) | 0 (0.0) |
Methotrexate | 1 (3.7) | 5 (5.0) |
Thalidomide | 0 (0.0) | 6 (5.9) |
Tacrolimus | 1 (3.7) | 1 (1.0) |
Cyclosporine A | 0 (0.0) | 1 (1.0) |
Nutritional therapies | 2 (7.4) | 33 (32.7) |
Other | 15 (55.6) | 46 (45.5) |
Corticosteroid status | ||
Intolerant | 0 | 6 (2.4) |
Dependent | 13 (37.1) | 23 (9.1) |
Not dependent or intolerant | 9 (25.7) | 21 (8.3) |
Unknown | 13 (37.1) | 202 (80.2) |
Duration of non-biologic therapy discontinued before index date, months, mean (SD)c | 1.2 (2.1) | 1.1 (2.5) |
Concomitant non-biologic therapy at index date, n (%) | 24 (68.6) | 108 (42.9) |
Aminosalicylates | 19 (54.3) | 77 (30.6) |
Corticosteroids | 8 (22.9) | 35 (13.9) |
Immunosuppressants | 5 (14.3) | 22 (8.7) |